Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Data From Routine Lung Cancer Visits Yield Research Insights

Publish date:: April 25, 2019

Key clinical point: Creating a database of clinical and genetic information from clinical visits is feasible and useful for oncology research.

Major finding: Among 3,522 patients with advanced disease, the median overall survival was 10.3 months and the 5-year survival rate was 3.8%.

Study details: The study population included 4,064 adults with non–small cell lung cancer.

Disclosures: The study was supported by Flatiron Health and Foundation Medicine, which are both owned by the Roche Group. Dr. Singal and several coauthors are employees of Foundation Medicine.

Citation:

Singal G et al. JAMA. 2019;321:1391-9.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lung Cancer

Two different radiation boost strategies reduce local failures in NSCLC,

Rechallenge ‘reasonable’ for some with small-cell lung cancer,

Black patients with ES-SCLC get less chemo but have better survival,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,